In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Drug-eluting balloon catheters in the endovascular treatment of patients with true left main bifurcation lesions

Session Poster Session 7

Speaker Associate Professor Daniil Maximkin

Congress : ESC Congress 2018

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Coronary Intervention: Devices
  • Session type : Poster Session
  • FP Number : P6368

Authors : D A Maximkin (Moscow,RU), OO Safonova (Moscow,RU), AG Chepurnoy (Moscow,RU), Z KH Shugushev (Moscow,RU)

Authors:
D.A. Maximkin1 , O.O. Safonova1 , A.G. Chepurnoy1 , Z.K.H. Shugushev1 , 1RUDN University - Moscow - Russian Federation ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1336-1337

Aim: To evaluate the effectiveness of drug-eluting balloons in patients with Left Main (LM) bifurcation stenosis.

Material: 128 patients with true bifurcation lesions of the LM were included in the study. All patients underwent “Provisional T” stenting of the LM coronary artery with the final kissing-dilatation technique. Depending on the balloon catheters used for the final kissing, the patients were randomized into 2 groups. Group I (n=64) - a kissing-dilatation performed with traditional NC balloon catheters, and group II (n=64) - who had a kissing-dilatation of the main bifurcation artery with a traditional NC balloon catheters, and a side branch - with drug-eluting balloon catheters. In addition, patients from group II also underwent kissing-predilatation with drug-eluting balloon catheters. Inclusion criteria: true bifurcation stenosis of the LMCA from QSA and IVUS data; SYNTAXscore <32. Primary endpoints: incidence of MACE - death, MI, re-interventions.

Results: All patients were implanted with drug-eluting stents. Survival of patients after PCI was 100% in both groups. All interventions are performed without complications. 6-month results were analyzed in all patients. After 6-months no cases of MACE were observed. In 3 patients (4.7%), group I showed signs of new-intima hyperplasia (restenosis up to 50%), repeated interventions were not performed. 12-month results were followed in 52 patients from group I and 48 patients from group II. In 1 patient (1.9%) from group I, and 1 patient (2.1%) from group II (p>0.05) there was a recurrence of angina. Myocardial ischemia is confirmed by stress tests, coronary angiography revealed stent restenosis up to 80%. Both patients underwent repeated interventions. Restenosis of the side branch of less than 50% according to QSA was detected in 5 patients (9.6%) from group I and in 4 patients (8.3%) from group II (p>0.05). In patients from group I, the average MLA in the side branch (LCX) after 12 months was 5.58±1.34 and 4.21±1.21 mm, respectively (p<0.05), compared with data after PCI; in the ostium of the side branch (LAD) - 6.34±1.56 and 5.28±1.14, respectively (p<0.05). In patients from Group II, the average MLA at the end of PCI and after 12 months were, respectively, 5.38±1.24 and 5.11±1.44 mm for the ostium of LCX (p>0.05) and 6.68±1.75 and 6.46±1.22 mm for the ostium of LAD (p<0.05). All patients had complete stent endothelization, with no signs of malapposition. There were no cases of late thrombosis of the stents.

Conclusion: The use of drug-eluting balloon catheters to perform “Provisional T” stenting of true LM bifurcation stenoses is highly effective and safe, as evidenced by a significant low incidence of restenosis of the side branch according to intravascular imaging methods without affecting the MACE frequency and can be considered as an alternative two-stent strategy of bifurcation stenting.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are